On August 29, HSBC Holdings PLC research issued a report on CHINA FEIHE (06186), projecting that the company will achieve a revenue compound annual growth rate of 2.4% and an EBIT compound annual growth rate of 5.5% from 2025 to 2028. The bank believes that margin improvement will be primarily driven by the government's proactive population policies, positioning CHINA FEIHE, as a listed company specializing in infant formula, to be among the first beneficiaries.

On August 28, CHINA FEIHE released its interim results for 2025. During the reporting period, the company achieved revenue of 91.5 billion yuan, net profit of 10.3 billion yuan, and cash and cash equivalents of 64.8 billion yuan, demonstrating solid operational fundamentals.

Based on robust performance and strong cash flow, CHINA FEIHE announced plans to allocate no less than 10 billion yuan for share repurchases. The company also expects to distribute approximately 10 billion yuan in interim dividends for 2025, with total dividend payments for 2025 not less than 20 billion yuan. Through active share buybacks to enhance earnings per share, the financial leverage effect will be significant.